Axsome Therapeutics (AXSM) Return on Capital Employed (2016 - 2026)
Axsome Therapeutics (AXSM) reported Return on Capital Employed of 65.96% for Q1 2026, up 1384.0% on a YoY basis from 4.44% in Q1 2025, and down 18.93% sequentially from 55.46% in Q4 2025.
Axsome Therapeutics (AXSM) Return on Capital Employed (2016 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 11 years of Return on Capital Employed data on file, last reported at 65.96% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1384.0% year-over-year to 65.96%; the trailing twelve-month figure through Mar 2026 stood at 65.96% (up 1384.0% YoY), and the FY2025 full-year result was 66.62%, up 1394.0% from the prior year.
- Return on Capital Employed retreated to 65.96% in Q1 2026, from 55.46% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 39.36% in Q3 2023 to a low of 212.43% in Q1 2022.
- A 5-year average of 81.88% and a median of 75.34% in 2022 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed slumped 15140 bps in 2022 and surged 15548 bps in 2023, its largest moves.
- Tracing AXSM's Return on Capital Employed over 5 years: stood at 75.34% in 2022, then jumped by 32 bps to 50.87% in 2023, then tumbled by 65 bps to 83.78% in 2024, then surged by 34 bps to 55.46% in 2025, then decreased by 19 bps to 65.96% in 2026.
- Business Quant data shows AXSM's Return on Capital Employed at 65.96% in Q1 2026, 55.46% in Q4 2025, and 72.2% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,462.92 Bn | 67,462.64 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,941.00 Bn | 1,940.94 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | -107.40% |
| 4 | BeOne Medicines | 473.07 Bn | 468.27 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 123.28 Bn | 116.03 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 70.12 Bn | 61.37 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.40 Bn | 62.40 Bn | - | - |
| 8 | Argenx Se | 56.45 Bn | 51.27 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 20.34% |
| 10 | Axsome Therapeutics | 12.33 Bn | 12.03 Bn | 176.48 Mn | -65.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.96% |
| Dec 31, 2025 | -55.46% |
| Sep 30, 2025 | -72.20% |
| Jun 30, 2025 | -82.91% |
| Mar 31, 2025 | -79.80% |
| Dec 31, 2024 | -83.78% |
| Sep 30, 2024 | -85.38% |
| Jun 30, 2024 | -84.82% |
| Mar 31, 2024 | -69.21% |
| Dec 31, 2023 | -50.87% |
| Sep 30, 2023 | -39.36% |
| Jun 30, 2023 | -45.08% |
| Mar 31, 2023 | -56.95% |
| Dec 31, 2022 | -75.34% |
| Sep 30, 2022 | -76.45% |
| Jun 30, 2022 | -155.98% |
| Mar 31, 2022 | -212.43% |
| Dec 31, 2021 | -157.60% |
| Sep 30, 2021 | -113.89% |
| Jun 30, 2021 | -81.35% |